Skerlj Renato 4
4 · X4 Pharmaceuticals, Inc · Filed Sep 10, 2020
Insider Transaction Report
Form 4
Skerlj Renato
Chief Scientific Officer
Transactions
- Sale
Common Stock
2020-09-09$8.05/sh−5,834$46,964→ 42,076 total
Footnotes (4)
- [F1]The reported transaction was effected pursuant to a Rule 10b5-1 trading plan.
- [F2]Includes sale of 1,660 shares to cover personal income tax obligation upon settlement of restricted stock unit award.
- [F3]The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $7.57 to $8.96, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]Of the shares of common stock reported, 11,666 shares represent unvested restricted stock units.